Heritage Investors Management Corp lowered its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 19.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 76,395 shares of the medical research company's stock after selling 17,891 shares during the period. Heritage Investors Management Corp's holdings in Exact Sciences were worth $4,293,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Thompson Investment Management Inc. raised its holdings in Exact Sciences by 17.8% during the 4th quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company's stock valued at $13,585,000 after buying an additional 36,505 shares during the last quarter. WCM Investment Management LLC lifted its stake in shares of Exact Sciences by 1,153.2% in the 3rd quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company's stock worth $12,388,000 after purchasing an additional 172,821 shares during the period. Simplify Asset Management Inc. lifted its holdings in Exact Sciences by 67.5% during the third quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company's stock valued at $1,994,000 after purchasing an additional 11,800 shares in the last quarter. Zacks Investment Management bought a new stake in shares of Exact Sciences during the third quarter valued at approximately $2,083,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in Exact Sciences by 59.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company's stock worth $22,868,000 after purchasing an additional 125,192 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors.
Exact Sciences Stock Down 0.9 %
Shares of EXAS traded down $0.41 on Friday, reaching $47.41. The company's stock had a trading volume of 3,106,807 shares, compared to its average volume of 2,341,992. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The firm has a fifty day moving average of $53.93 and a 200-day moving average of $59.72. The stock has a market capitalization of $8.81 billion, a PE ratio of -8.51 and a beta of 1.24.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $713.42 million for the quarter, compared to analysts' expectations of $701.45 million. Equities analysts predict that Exact Sciences Co. will post -0.58 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on EXAS. Robert W. Baird lowered their price objective on shares of Exact Sciences from $70.00 to $67.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. BTIG Research increased their target price on Exact Sciences from $65.00 to $75.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Bank of America reduced their price objective on Exact Sciences from $72.00 to $65.00 and set a "buy" rating for the company in a research note on Thursday, February 20th. Evercore ISI cut their price objective on Exact Sciences from $80.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. Finally, William Blair restated an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $71.94.
View Our Latest Report on EXAS
Exact Sciences Company Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Further Reading
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
